Skip to content
Specimen Atlas of Research Peptides81 plates · MIT
Side-by-side · Research reference

N-Acetyl Epitalon AmidatevsTestagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED12/45 cited
BAnimal-MechanisticHUMAN-REVIEWED11/41 cited
N-Acetyl Epitalon Amidate
Bioregulator Tetrapeptide · Khavinson School
10 passagesExtra divisionsKhavinson 2004
Telomerase+Enzyme inductionKhavinson 2003
4-AATetrapeptide
SQ · Variable protocols
Testagen
Bioregulator Peptide · Khavinson School
Lys-Glu-Asp-GlySequenceFedoreyeva 2011
NuclearLocalizationFedoreyeva 2011
TesticularTissue target
SQ · Abdomen · Cyclical

01Mechanism of Action

Parameter
N-Acetyl Epitalon Amidate
Testagen
Primary target
DNA promoter regions (telomerase, RNA polymerase II, retinal genes)
Testicular tissue; proposed nuclear DNA interaction
Pathway
Peptide → DNA complementary binding → Gene transcription initiation → Telomerase catalytic subunit expression
Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011
Downstream effect
Telomerase enzymatic activity induction, telomere elongation to early-passage length, extension of replicative lifespan in human somatic cellsKhavinson 2003Khavinson 2004
Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011
Feedback intact?
Unknown — no HPG axis data
Origin
Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from pineal extract bioregulator research; N-acetyl and C-amide modifications enhance plasma stability
Khavinson bioregulator school — isolated from testicular tissue peptide fractions
Antibody development

02Dosage Protocols

Parameter
N-Acetyl Epitalon Amidate
Testagen
Standard dose
No standardized human dosing in indexed literature
In vitro protocols use direct culture addition; human clinical dosing protocols are in Russian-language literature outside PubMed scope.
Frequency
Not specified in candidate papers
Once daily or alternate days
Evidence basis
In vitro human cell cultureKhavinson 2004Khavinson 2003
Animal mechanistic / in vitro onlyFedoreyeva 2011
Cell culture protocol
Addition to human fetal fibroblast culture induced telomerase activity and telomere elongation to early-passage lengthKhavinson 2004
Cells made 10 extra divisions (44 passages total vs 34 in control).
Duration
Chronic treatment in aging culture
Sustained effect through late passages.
Modification stability
N-acetyl + C-amide caps enhance peptidase resistance
Standard strategy for tetrapeptide stabilization; specifics not quantified in candidates.
Typical protocol (anecdotal)
100–200 mcg / day
No published human dosing studies; derived from Russian bioregulator practice.
Cycle length
10–20 days on, 10–14 days off
Bioregulator tradition uses pulsed cycles; no controlled data.
Route
Subcutaneous
Reconstitution
Sterile water or bacteriostatic saline
Half-life
Unknown — likely minutes (short peptide)

04Side Effects & Safety

Parameter
N-Acetyl Epitalon Amidate
Testagen
Human safety data
Not available in indexed literature
Candidate papers describe in vitro and animal models only.
Theoretical telomerase risk
Telomerase activation in somatic cells raises theoretical oncogenic transformation concern
In vitro observations
No cytotoxicity reported in human fetal fibroblast cultureKhavinson 2004
Injection site reactions
Erythema, mild irritation (potential)
Systemic effects
Unknown — no human safety data
Hormonal impact
No published data on testosterone, LH, FSH effects
Long-term safety
Unknown — no long-term studies
Absolute Contraindications
N-Acetyl Epitalon Amidate
  • ·Active malignancy or history of cancer — telomerase reactivation may promote tumor cell immortalization
Testagen
  • ·Active testicular malignancy
Relative Contraindications
N-Acetyl Epitalon Amidate
  • ·Individuals with hereditary cancer syndromes or high genetic cancer risk
Testagen
  • ·Hormone-sensitive cancers (no data; theoretical caution)
  • ·Pregnant or breastfeeding (no data)

05Administration Protocol

Parameter
N-Acetyl Epitalon Amidate
Testagen
1. Route
Subcutaneous injection assumed based on peptide class; no specific protocol in candidate papers.
Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.
2. Reconstitution
Standard bacteriostatic water for lyophilized peptides. Exact volume not specified in indexed literature.
Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).
3. Storage
Lyophilized: -20 °C, desiccated. Reconstituted: refrigerate 2–8 °C. N-acetyl and C-amide modifications improve stability vs unprotected tetrapeptide.
Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.
4. Clinical protocols
Human dosing schedules published in Russian-language clinical literature; not indexed in PubMed candidate set.
Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.
5. Cycle protocol
10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.

06Stack Synergy

N-Acetyl Epitalon Amidate
+ Thymalin
Moderate
View Thymalin

Both are Khavinson-school bioregulators with epigenetic mechanisms. Thymalin targets thymic transcription factors for immune function, while Epitalon targets telomerase and pineal-axis genes. Combined use theoretically addresses dual axes of aging: replicative senescence and immune decline. Multi-target bioregulator strategy per Khavinson gerontology framework.

Epitalon
Protocol not defined in indexed literature
Thymalin
Tissue-specific bioregulator · separate dosing
Rationale
Complementary transcriptional targets
Primary benefit
Dual-axis aging intervention: cellular senescence + immune restoration
Testagen
— no documented stacks